Iterative Health, a healthcare technology and services company accelerating clinical research, has closed a $77 million Series C financing round led by Intrepid Growth Partners and GV (Google Ventures), joined by new investors EDBI, an arm of SG Growth Capital, and a prominent family office, with participation from existing investors Insight Partners and Obvious Ventures.
Clinical trials are the critical bridge between scientific discovery and patient care, yet more than half of research sites enroll one or fewer patients per study, and nearly 90% of U.S.-based trials fail to meet enrollment targets on time. Iterative Health addresses these systemic challenges by building a high-performing, multispecialty clinical research network that embeds research directly into clinical care, placing site success at the center of trial execution.
The company’s global network now includes more than 100 research sites across North America, Europe, India, and Australia, alongside partnerships with more than 40 pharmaceutical, biotech, medical device, and contract research organizations. Compared to industry benchmarks for inflammatory bowel disease trials, the network delivers 2x faster site activation, reducing startup timelines by up to three months, and 3x higher patient enrollment rates, with an average of more than two IBD patients randomized every business day across the global site network.
The new funding will support expansion into additional therapeutic areas beyond gastroenterology and hepatology, including cardiology and obesity, as well as continued geographic growth and deeper partnerships with leading provider organizations including GI Alliance, OneGI, and U.S. Heart and Vascular. As part of the financing, Ajay Agrawal, Co-Founder and Partner at Intrepid Growth Partners, will join Iterative Health’s Board of Directors, and Anthony Philippakis, General Partner at GV, will join as a board observer.
KEY QUOTES:
“Every delay in a clinical trial is a delay for patients whose outcomes depend on faster access to innovation. By keeping our physician partners and their patients at the center of our model, we’ve built a system that delivers high-performance site execution at scale.”
Jonathan Ng, MBBS, Founder and CEO, Iterative Health
“Iterative Health is a perfect example of this thesis, having purpose-built its proprietary technology to power a revolutionary clinical trial network that delivers unparalleled speed and scale to the pharmaceutical sector.”
Ajay Agrawal, Co-Founder and Partner, Intrepid Growth Partners
“Clinical research remains the biggest bottleneck in drug development today. Iterative Health is solving this by using AI to accelerate trial enrollment times and bring new medicines to market faster.”
Anthony Philippakis, General Partner, GV
